Prostate Cancer: Metabolic Remodeling in Expressed Prostatic Secretions Reveals Cellular Structural Changes Measured by mpMRI

Early detection of prostate cancer (PC) versus benign prostatic hyperplasia (BPH) remains difficult; this study used NMR-based metabolomics on 64 expressed prostatic secretion (EPS) samples to identify key biomarkers. Multivariate analyses and machine learning models highlighted citrate, glutamate, myo-inositol, and cis-aconitate as discriminative metabolites. These showed strong diagnostic potential, correlating with PSA, mpMRI (PI-RADS, ADC), and Gleason score, supporting noninvasive early PC diagnosis.